Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2700 participants.
Also called NCT01761786
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,700 participants
- Sponsor
- Registry
-
NCT01761786
-
- Other papers using this trial's data
- A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Italy, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01761786. Randomized; single masking; primary purpose treatment. Start 2011-06 (actual); primary completion 2019-04-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
- Condition
- Myocardial Infarction
- Condition
- STEMI
- Intervention (Genetic)
- CYP2C19 genotyping
- Lead sponsor
- Vera HM Deneer
- Collaborator
- Isala
- Collaborator
- Meander Medical Center
- Collaborator
- UMC Utrecht
- Collaborator
- University Medical Center Groningen
- Collaborator
- OLVG
- Collaborator
- Onze Lieve Vrouw Hospital
- Collaborator
- Amphia Hospital
- Collaborator
- ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator
- Federico II University
- Collaborator
- Rijnstate Hospital
Record details
- Record id
cardio:ct-nct01761786- Content hash
b8e5dd0262598d1c35f01b4e57e950f0639f9116129b802e108ba4fde1e0a25f